To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Plerixafor (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms CAM-PLEX
- 21 Dec 2018 Status changed from recruiting to completed.
- 24 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Mar 2019.
- 24 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.